Dosing & Uses
Non-Small Cell Lung Cancer (NSCLC)
Pending FDA approval for first-line treatment of nonsquamous non-small cell lung cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy
Pharmacology
Mechanism of Action
Fully human monoclonal immunoglobulin G4 (IgG4) antibody that targets checkpoint inhibitor PD-1 (programmed death 1) and blocks its interaction with PD-L1 and PD-L2; this results in releasing the PD-1 pathway-mediated inhibition of the immune response, including antitumor immune response, thereby decreasing tumor growth
Binding of the PD-1 ligands PD-L1 and PD-L2 to the receptor found on T cells inhibits T-cell proliferation and cytokine production
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.